Skip to Main Content
Table 2

Response rates vs. age in Phase 2 studies of 142 patients with CD33 positive AML in first relapse treated with gemtuzumab ozogamicin

Type of remission201/202/203 (n = 142)<60 yr (n = 62)≥60 yr (n = 80)
CR    
 No. (%) of patients 23 (16) 11/62 (18) 12/80 (15) 
 95% CIsa (11, 23) (9, 30) (8, 25) 
CRp    
 No. (%) of patients 19 (13) 10/62 (16) 9/80 (11) 
 95% CIs (8, 20) (8, 28) (5, 20) 
OR (CR + CRp)    
 No. (%) of patients 42 (30) 21/62 (34) 21/80 (26) 
 95% CIs (22, 38) (22, 47) (17, 37) 
Type of remission201/202/203 (n = 142)<60 yr (n = 62)≥60 yr (n = 80)
CR    
 No. (%) of patients 23 (16) 11/62 (18) 12/80 (15) 
 95% CIsa (11, 23) (9, 30) (8, 25) 
CRp    
 No. (%) of patients 19 (13) 10/62 (16) 9/80 (11) 
 95% CIs (8, 20) (8, 28) (5, 20) 
OR (CR + CRp)    
 No. (%) of patients 42 (30) 21/62 (34) 21/80 (26) 
 95% CIs (22, 38) (22, 47) (17, 37) 
a

CI, confidence interval.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept